webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More
  1. Home
  2. Products
  3. ADC Cytotoxin
  4. Microtubule/Tubulin
  5. MMAE

MMAE

  CAS No.: 474645-27-7   Cat No.: BADC-00324   Purity: ≥98.0% by HPLC HNMR HPLC MS 4.5  

Monomethyl Auristatin E (MMAE) is a synthetic analog of dolastatin 10 that similarly inhibits tubulin polymerization and exhibits potent cytotoxicity. It is commonly conjugated with monoclonal antibodies directed at antigens specific to cancer cells for tumor-directed cytotoxicity.

MMAE

Structure of 474645-27-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C39H67N5O7
Molecular Weight
717.98
Target
Microtubule/Tubulin
Shipping
Ice packs
Shipping
Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
25 mg $298 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
MMAE; Vedotin; Monomethyl auristatin E; Monomethylauristatin E; N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
IUPAC Name
(2S)-N-[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
Canonical SMILES
CC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC
InChI
InChI=1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t25-,26+,27+,29-,30+,32-,33-,34-,35+,36+/m0/s1
InChIKey
DASWEROEPLKSEI-UIJRFTGLSA-N
Density
1.088±0.06 g/cm3 (Predicted)
Solubility
Soluble in DMSO (Slightly), Methanol (Slightly, Sonicated); Insoluble in Water
Melting Point
>90°C (dec.)
Flash Point
482.1±34.3 °C
Index Of Refraction
1.519
PSA
149.54000
Vapor Pressure
0.0±0.3 mmHg at 25°C
Appearance
White to Off-white Solid
Shipping
Ice packs
Storage
Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
Pictograms
Irritant; Health Hazard
Signal Word
Warning
Boiling Point
873.5±65.0 °C at 760 mmHg
In Vitro
Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells.
In Vivo
Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models.
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT05113459Gastric CancerPhase 22021-11-09Guoxin LiNot yet recruiting
NCT03187210LymphomaPhase 1, Phase 22021-08-05University Hospital Inselspital, BerneRecruiting
NCT04679012Richter SyndromePhase 22021-09-22Weill Medical College of Cornell UniversityNot yet recruiting
NCT05006664Lymphoma, T-Cell, PeripheralPhase 22021-09-01Czech Lymphoma Study GroupNot yet recruiting
NCT02227433Hodgkin LymphomaPhase 22020-12-22Fondazione Italiana Linfomi ONLUSCompleted
1.An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H1, Yu C2, Jiang J3, Huang C2, Yao X1, Xu Q2, Yu F2, Lou L4, Fang J1,5,6. Cancer Biol Ther. 2016 Apr 2;17(4):346-54. doi: 10.1080/15384047.2016.1139248. Epub 2016 Feb 6.
Antibody-drug conjugate (ADC) is a novel class of therapeutics for cancer target therapy. This study assessed antitumor activity of ADC with an antimitotic agent, monomethyl auristatin E (MMAE) and a humanized monoclonal anti-HER2 antibody, hertuzumab, in gastric cancer. The efficacy of hertuzumab-MC-Val-Cit-PAB-MMAE (hertuzumab-vcMMAE) on human epidermal growth factor receptor 2 (HER2) positive human gastric cancer cells, NCI-N87, was evaluated in vitro and in vivo. The cytotoxicity of hertuzumab was significantly enhanced after conjugation with MMAE. Compared to trastuzumab, hertuzumab had a higher affinity to HER2 and had more potent antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro. After conjugation with MMAE, the binding specificity for HER2 was not affected. Furthermore, the internalization of hertuzumab-vcMMAE in HER2 positive gastric cancer cells was verified. Although the conjugation of hertuzumab and MMAE decreased the ADCC effect, the overall cytotoxicity was dramatically increased in HER2 positive gastric cancer cells.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC Cytotoxin with Linker

ADC Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

ADC Linker

Precise Conjugation For Success

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Duocarmycin MB | Seco-Duocarmycin MA | Duocarmycin TM | Duocarmycin A | Seco-Duocarmycin SA | Mc-VC-PAB-SN38 | 7-MAD-MDCPT | Seco-Duocamycin GA | CL2A-SN-38 DCA | DSP Crosslinker | MMAE
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout